Lipid lowering drugs (LLDs) v placebo for decrease of coronary artery disease (CAD) events and mortality and all cause mortality in patients with no history of CAD*
| Unweighted event rates | ||||
|---|---|---|---|---|
| Outcomes at median 5 years | LLDs | Placebo | RRR (95% CI) weighted | NNT (CI) weighted |
| *Abbreviations defined in glossary; RRR, NNT, and CI calculated from data provided by the author. | ||||
| CAD events in all 4 studies | 4.2% | 5.8% | 28% (19 to 36) | 69 (49 to 120) |
| CAD events in 2 statin studies | 3.5% | 5.2% | 33% (21 to 43) | 69 (49 to 120) |
| CAD mortality in all 4 studies | 0.9% | 1.2% | 25% (2 to 43) | Not significant |
| CAD mortality in 2 statin studies | 0.7% | 1% | 27% (−5 to 49) | Not significant |
| All cause mortality in all 4 studies | 2.8% | 3.1% | 8% (−7 to 21) | Not significant |
| All cause mortality in 2 statin studies | 2.8% | 3.2% | 12% (−6 to 28) | Not significant |